• Salman . Faculty of Pharmacy Andalas University
  • Ardiansyah . Faculty of Pharmacy Andalas University
  • Ellyza Nasrul Faculty of Medicine Andalas University
  • Harrizul Rivai Faculty of Pharmacy Andalas University
  • Elfi Sahlan Ben Faculty of Pharmacy Andalas University
  • Erizal Zaini Faculty of Pharmacy Andalas University


Objective: The aim of the current study was to prepare an amorphous solid dispersion of ketoprofen in polymer PVP K-30 by solvent co-evaporation technique and to characterize the physicochemical properties.

Methods: An amorphous solid dispersion of ketoprofen, a water insoluble non-steroidal anti- inflammatory drug with polyvinyl pyrrolidone K-30, were prepared by solvent co-evaporation method at drug to polymer ratios 1:1, 1:3, 1:5 and 1:9 (w/w). Physicochemical properties of the solid drug were evaluated by X-ray powder diffractometry (XRPD), differential thermal analysis (DTA) and scanning electron microscopy (SEM). Dissolution studies were conducted according to the USP paddle method.

Results: The X-ray powder diffraction and differential thermal analysis showed that ketoprofen was transformed from a crystalline phase to an amorphous state, as showed by disappearance of its characteristic of diffraction peaks and an endothermic peak. SEM Microphoto of amorphous solid dispersion showed homogeneous size and morphology. In addition, ketoprofen in amorphous solid dispersion showed better dissolution rate compared to crystalline drugs. The dissolution efficiency (DE) of ketoprofen from its amorphous solid dispersion increased with an increasing ratio of polymer.

Conclusion: The study has shown that dispersions of ketoprofen into water-soluble polymer PVP K-30 formed an amorphous ketoprofen in solid dispersion system. All amorphous solid dispersion of ketoprofen in PVP K-30 prepared by solvent co-evaporation demonstrated a significant improvement in dissolution rate of ketoprofen compared to pure ketoprofen.


Keywords: Solvent co-evaporation, Amorphous solid dispersion, Ketoprofen, Polyvinyl pyrrolidone K-30


Download data is not yet available.


1. Mura P, Moyano JR, Gonzalez-Rogriguez ML, Rabasco-Alvarez AM, Cirri M, Maestrelli F. Characterization and dissolution properties of ketoprofen in binary and ternary solid dispersion with polyethylene glycol and surfactants. Drug Dev Ind Pharm 2005;31:425–34.
2. Halim A, Hamdeni S, Zaini E. Enhanced dissolution rate of trimethoprim by Co-grinding technique with polyvinylpyrrolidone K-30 polymer. Indonesian J Pharm Sci 2013;11:1-6.
3. Masuda T, Yoshihashi Y, Yonemochi E, Fujii K, Uekusa H, Terada K. Cocrystallization and amorphization by drug-excipient interaction improves the physical properties of acyclovir. Int J Pharm 2012;422:160-9.
4. Sathigari S, Chadha G, Lee Y-H P, Wright N, Parsons DL, Rangari VK, et al. Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes. AAPS Pharm Sci Tech 2009;10:81-7.
5. Bani-Jaber A, Hamdan I, Al-Khalidi B. Sodium mefenamate as a solution for the formulation and dissolution problems of mefenamic acid. Chem Pharm Bull 2007;55:1136-40.
6. Hildebrand GE, Mueller-Goymann CC. Ketoprofen sodium: preparation and its formation of mixed crystals with ketoprofen. J Pharm Sci 1997;86(7):854-7.
7. Lu WL, Zhang Q, Zheng L, Wang H, Li RL, Zhang LF, et al. Antipyretic, Analgesic and anti-inflammatory activities of ketoprofen-β-cyclodextrin inclusion complexes in animals. Biol Pharm Bull 2004;27(10):1515-20.
8. Mura P, Faucci MT, Parrini PL. Effects of grinding with microcrystalline cellulose and cyclodextrin on the ketoprofen physicochemical properties. Drug Dev Ind Pharm 2001;27(2):119-28.
9. Leuner C, DressmanJ. Improving drug solubility for oral drug delivery using solid dispersions. Eur J Pharm Biopharm 2000;50:47-60.
10. Brough C, Williams RO. Amorphous solid dispersions and nano-crystal technologies for poorly water soluble drug delivery. Int J Pharm 2013;453:157-66.
11. Grohganz H, Lobmann K, Priemel P, Jensen KT, Graeser K, Strachan C et al. Amorphous drugs and dosage forms. J Drug Del Sci Tech 2013;23:403-8.
12. Adeyeye MC. Drug-Excipient Interaction Occurences During Solid Dosage Form Development. In Adeyeye MC, Brittain HG, editors. Preformulation in Solid Dosage Form Development. USA: Informa Healthcare Inc; 2008. p. 361-430.
13. Sathigari SK, Radhakrishnan VK, Davis VA, Parsons DL, Babu RJ. Amorphous state characterization of efavirenz-polymer hot melt extrusion system for dissolution enhancement. J Pharm Sci 2012;101:3456-64.
14. Aguiar AJ, Krc J, Kinkel AW, Samyn JC. Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol pamitate. J Pharm Sci 1967;56:847-53.
15. Kogermann K, Penkina A, Predbannikova K, Jeeger K, Veski P, Rantanen J et al. Dissolution testing of amorphous solid dispersions. Int J Pharm 2013;444:40-6.
16. Zaini E, Sumirtapura YC, Soewandhi SN, Halim A, Uekusa H, Fujii K. Cocrystalline phase transformation of binary mixture of trimethoprim and sulfamethoxazole by slurry technique. Asian J Pharm Clin Res 2010;3:26-9.
17. Chiou WL, dan Riegelman S. Pharmaceutical application of solid dispersion systems. J Pharm Sci 1971;60:1281-302.
18. Khan KA. The concept of dissolution efficiency. J Pharm Pharm 1975;27:48.
438 Views | 2605 Downloads
How to Cite
., S., A. ., E. Nasrul, H. Rivai, E. S. Ben, and E. Zaini. “PHYSICOCHEMICAL CHARACTERIZATION OF AMORPHOUS SOLID DISPERSION OF KETOPROFEN–POLYVINYLPYRROLIDONE K-30”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 7, no. 2, Dec. 2014, pp. 209-12,
Original Article(s)